Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 60 Pages
|Effient(急性冠狀動脈症候群)- 預測與市場分析 Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 60 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
Effient is an antiplatelet blood thinner that inhibits the P2Y12 receptor. Inhibition of P2Y12 blocks key signaling events in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during the acute phase of ACS, and as a once-daily 10mg maintenance dose during the chronic phase of ACS for the first year following an ACS event. Effient is indicated to reduce the occurrence of CV events in ACS patients managed with PCI.